Can­cer drug prices rise in the US de­spite an in­creas­ing­ly com­pet­i­tive mar­ket — re­port

As De­moc­rats’ hopes of Medicare drug price ne­go­ti­a­tions seem fur­ther out of reach, a new study shows that in­creased com­pe­ti­tion in the can­cer drug mar­ket has not, in fact, led to price de­creas­es — well, not in the US at least.

Be­tween 2009 and 2020, prices in­creased — with one ex­cep­tion — with­in and across all 12 can­cer drug class­es stud­ied in the US, where­as prices in Switzer­land and Ger­many gen­er­al­ly de­creased over time or did not rise more than in­fla­tion, ac­cord­ing to a re­cent pub­li­ca­tion in the Lancet. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.